And Generic Formulations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The drug major's consolidated net profit jumped 18.7% to Rs 464.37 crore on 0.8% fall in net sales to Rs 3,759.27 crore in Q4 March 2021 over Q4 March 2020. Profit before tax rose 4.4% to Rs 518.38 crore in Q4 March 2021 from Rs 496.36 crore in Q4 March 2020. EBITDA (before forex & other income) soared 35.1% to Rs 707.50 crore in Q4 March 2021 as against Rs 523.70 crore in Q4 March 2020. EBITDA margin improved to 18.8% in Q4 FY21 compared with 13.8% in Q4 FY20. Net debt as on 31 March 2021 stood at Rs 662.60 crore while the net debt-equity for the company was at 0.05 as on 31 March 2021. Com...

Read more about Lupin incorporates subsidiary in US on Business Standard. The drug major has incorporated a wholly-owned subsidiary in the USA under the name, Lupin Oncology Inc. (LOI).

Lupin Pharma, a subsidiary of the drug major, announced a partnership with Endoceutics, a women's health focused innovative Canadian biotech company, to commercialize Intrarosa in Canada. Intrarosa is Endoceutic's flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone. Intrarosa was developed in Quebec City, Canada by Endoceutics and will be manufactured in their facilities in Mont Saint Hilaire, Canada. Intrarosa is indicated for postmenopausal vulvovaginal atrophy, it is a vaginal ovule containing 6.5 m...